Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial - PubMed
7 hours ago
- #immunotherapy
- #clinical trial
- #non-small-cell lung cancer
- Comparison of benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (NSCLC).
- Phase 3 CAMPASS trial conducted in 79 centers across China with 531 patients enrolled.
- Primary endpoint was progression-free survival assessed by blinded independent review committee.
- Median progression-free survival was 11.0 months for benmelstobart plus anlotinib vs 7.1 months for pembrolizumab (HR 0.70, p=0.0057).
- Higher incidence of grade 3 or worse treatment-related adverse events in benmelstobart plus anlotinib group (59%) vs pembrolizumab group (29%).
- Most frequent adverse events included hypertension (26% vs 3%) and serious events like haemoptysis and immune-mediated pulmonary diseases.
- Five treatment-related deaths in benmelstobart plus anlotinib group vs four in pembrolizumab group.
- Benmelstobart plus anlotinib showed longer progression-free survival, suggesting potential as first-line treatment option.
- Longer-term follow-up needed to assess effects on overall survival.
- Funding provided by Chia Tai Tianqing Pharmaceutical Group.